Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2019

Mar 12, 2019

30198_dirs_2019-03-11_a3706f85-8e52-4f1e-8030-9caefdfcf284.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2019-03-08

Reporting Person: Abbey Donald (EVP Quality and Regulatory Aff)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-03-08 Common Stock A 14987 $0.001 Acquired 103076 Direct

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2: Included in this number are 68,158 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019.